Study

Design

Population

Outcomes

Results

Adjustments

Comments

 

 

 

 

tablets (RoM 1.8, 95% CI 1.3-2.5)

Solvents (RoM 1.8, 95% CI 1.4-2.2)

Pesticides (RoM 1.7, 95% CI 1.4-2.0)

Insect repellents (RoM 1.3, 95% CI 1.1-1.5)

No association with self-reports of immunizations or chemical exposure

 

 

Multiple Sclerosis

Barth et al., 2009 (Update)

Mortality cohort study, follow-up through 2004 of same cohort as Kang and Bullman (2001)

621,901 US male GWVs and 746,247 nondeployed male veterans

Mortality due to multiple sclerosis (McDonald criteria)

GWVs (6 cases) compared to era veterans (13 cases) MRR 0.67 (95% CI 0.24-1.85)

Race, service branch, type of unit, age, marital status

 

Amyotrophic Lateral Sclerosis (ALS)

Horner et al., 2003 (Vol. 4)

Retrospective cohort

All active, GWVs (1990-1991) compared with NDVs

ALS

All deployed forces, significant increased risk of ALS (RR = 1.92, 95% CL −1.29-2.84)

Age-adjusted average, annual 10-year incidence; attributable risk

Case ascertainment through screening of VA and DoD medical databases and benefit files (and TriCare) by ICD-9 code for ALS or riluzole use; tollfree telephone enrollment; Internet notices; mass mailings to neurologists, VA centers, and veteran service organizations



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement